Thanks Lia.
I was hoping to get some comments on the inputs and assumptions in the model. In particular, are there any opinions on the percentage of patients that will use Afrezza when sales are fully ramped up, and also on the ramp up percentages over the next ten years?
I would also assume that the rest of the world would contribute at least as much income to Mannkind as the US potentially does, but the ramp up would probably be a bit slower. If this is true then the global value, using this model with the current assumptions, for Mannkind is close to $20 per share.
I expected to get some disagreement on some of the assumptions. Surely not everyone agrees or the share price would already reflect more of the value.
